TCM
MRNA icon

Tradewinds Capital Management’s Moderna MRNA Stock Holding History

Tradewinds Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-195
Closed -$5.38K – 697
2025
Q2 		$5.38K Sell
195
-12
-6% -$316 ﹤0.01% 403
2025
Q1 		$5.87K Buy
+207
New +$7.35K ﹤0.01% 405
2024
Q1 		– Sell
-8
Closed -$796 – 568
2023
Q4 		$796 Hold
8
– – ﹤0.01% 397
2023
Q3 		$827 Hold
8
– – ﹤0.01% 400
2023
Q2 		$972 Hold
8
– – ﹤0.01% 385
2023
Q1 		$1.23K Hold
8
– – ﹤0.01% 372
2022
Q4 		$1.44K Hold
8
– – ﹤0.01% 386
2022
Q3 		$1K Sell
8
-25
-76% -$3.79K ﹤0.01% 380
2022
Q2 		$5K Sell
33
-124
-79% -$17.7K ﹤0.01% 274
2022
Q1 		$27K Buy
157
+4
+3% +$673 ﹤0.01% 333
2021
Q4 		$39K Sell
153
-23
-13% -$6.72K 0.01% 285
2021
Q3 		$68K Sell
176
-57
-24% -$21K 0.01% 196
2021
Q2 		$55K Sell
233
-415
-64% -$74.2K 0.01% 233
2021
Q1 		$85K Hold
648
– – 0.02% 169
2020
Q4 		$68K Buy
648
+526
+431% +$53.2K 0.01% 184
2020
Q3 		$9K Sell
122
-78
-39% -$5.44K ﹤0.01% 411
2020
Q2 		$13K Buy
+200
New +$11K ﹤0.01% 355

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Tradewinds Capital Management's MRNA Position: Q3 2025 in Review

Tradewinds Capital Management sold out of Moderna (MRNA) in Q3 2025, closing a stake of 195 shares — an estimated $5.38K sold.

Tradewinds Capital Management first reported a position in MRNA in Q2 2020 and held it in 17 quarters. The position peaked at $85K in Q1 2021. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Tradewinds Capital Management reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Tradewinds Capital Management sold 195 Moderna shares in Q3 2025, an estimated $5.38K.
  • Tradewinds Capital Management first reported a position in Moderna in Q2 2020 and held it in 17 quarters.
  • Tradewinds Capital Management's Moderna position peaked at $85K in Q1 2021.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Tradewinds Capital Management's 13F filing for Q3 2025, filed 21 Oct 2025.